Canadian isotope manufacturer MDS Nordion has received Canadian Nuclear Safety Commission (CNSC) authorization to restart low-power commissioning of its Maple 1 reactor at Chalk River, ON, near its Ottawa headquarters.
When fully operational, the reactor, along with its twin Maple 2 and a new processing facility, will be capable of supplying all of the world’s demand for a broad range of medical isotopes, including molybdenum-99, iodine-131, and xenon-133, according to the company. The reactors will be the only ones dedicated exclusively to production of medical isotopes, according to the agency.
Problems encountered in July 2000 caused the CNSC to temporarily halt commissioning of the reactor. Now that it is back up, MDS is proceeding with procedures to start active commissioning of the second unit. The company gave no timetable for completion of the facility.
By AuntMinnie.com staff writersOctober 29, 2002
Related Reading
MDS Nordion gets regulatory approvals, July 11, 2002
MDS Nordion focuses on oncology software solutions, June 28, 2002
MDS expands manufacturing facilities, June 12, 1002
MDS Nordion shows oncology info management system, November 5, 2001
MDS Nordion to build new cyclotron, July 9, 2001
Copyright © 2002 AuntMinnie.com
